Table 1

Kinetic parameters of LpA-I, LpA-I:A-II, apoA-II, and plasma apoA-I after treatment with fenofibrate, atorvastatin, or placebo

FenofibrateAtorvastatinPlaceboGroup differences (P)
Fenofibrate vs. placeboAtorvastatin vs. placeboFenofibrate vs. atorvastatin
FCR (pools/day)
    LpA-I0.54 ± 0.060.44 ± 0.070.44 ± 0.060.10 ± 0.08 (0.186)0.01 ± 0.06 (0.825)0.10 ± 0.06 (0.115)
    LpA-I:A-II0.29 ± 0.020.26 ± 0.030.25 ± 0.010.04 ± 0.01 (0.015)0.01 ± 0.02 (0.699)0.03 ± 0.03 (0.028)
    ApoA-II0.29 ± 0.020.26 ± 0.030.25 ± 0.010.04 ± 0.01 (0.015)0.01 ± 0.02 (0.699)0.03 ± 0.03 (0.028)
    ApoA-I0.33 ± 0.020.29 ± 0.030.29 ± 0.010.04 ± 0.02 (0.005)0.01 ± 0.02 (0.948)0.04 ± 0.02 (0.004)
Production rate (mg · kg−1 · day−1)
    LpA-I6.41 ± 0.625.50 ± 1.086.14 ± 1.160.27 ± 1.03 (0.725)−0.64 ± 1.21 (0.589)0.91 ± 0.83 (0.855)
    LpA-I:A-II11.90 ± 1.109.18 ± 0.769.18 ± 0.672.72 ± 0.63 (<0.001)−0.01 ± 0.44 (0.799)2.71 ± 0.90 (<0.001)
    ApoA-II4.88 ± 0.363.37 ± 0.293.41 ± 0.241.47 ± 0.24 (<0.001)−0.03 ± 0.26 (0.885)1.50 ± 0.41 (<0.001)
    ApoA-I17.88 ± 0.9914.52 ± 1.0814.41 ± 0.713.47 ± 1.02 (0.002)0.11 ± 0.85 (0.540)3.36 ± 1.24 (<0.001)
Plasma concentration (g/l)
    ApoA-I in LpA-I0.28 ± 0.030.30 ± 0.050.30 ± 0.03−0.01 ± 0.02 (0.584)0.001 ± 0.03 (0.983)−0.01 ± 0.03 (0.569)
    ApoA-I in LpA-I:A-II0.92 ± 0.060.82 ± 0.050.84 ± 0.050.08 ± 0.04 (0.016)−0.01 ± 0.04 (0.352)0.1 ± 0.04 (0.002)
    ApoA-II0.38 ± 0.020.29 ± 0.010.31 ± 0.010.07 ± 0.01 (<0.001)−0.01 ± 0.01 (0.156)0.08 ± 0.01 (<0.001)
    ApoA-I1.20 ± 0.061.11 ± 0.041.13 ± 0.050.07 ± 0.03 (0.010)−0.01 ± 0.04 (0.597)0.09 ± 0.03 (0.003)
  • Data are means ± SEM unless otherwise indicated. ApoA-I and apoA-II kinetics were determined from direct measurements of the corresponding tracer enrichment. The primary enrichment data for apoA-I and apoA-II were used to calculate LpA-I and LpA-I:A-II kinetic parameters. Values in bold are statistically significant.